Polmacoxib

Overview

Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC 50 around 0.1 μg/ml) and carbonic anhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > COX | Products > Signaling Pathways > Carbonic Anhydrase

Product Information

• Catalog No.: HY-16726
• CAS No.: 301692-76-2
• Molecular Formula: C18H16FNO4S
• Molecular Weight: 361.39
• Purity: 99.70%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (5.76 mM); Clear solution
• Availability: In-stock

Source

Original product source